Aeterna Zentaris is a specialty biopharmaceutical company with its focus on developing novel treatments in oncology and endocrinology. The company’s pipeline encompasses compounds from drug discovery to regulatory approval. Its lead drug development programs include zoptarelin doxorubicin (AEZS-108), a hybrid molecule composed of synthetic peptide carrier linked to doxorubicin, specifically targeting LHRH receptor expressing tumors; and macimorelin acetate (AEZS-130), which has received FDA orphan drug designation as a diagnostic test for growth hormone deficiency. For more information, visit the company’s Web site at www.aezsinc.com.